Genetic Abnormalities Detected in Non-Hodgkin Lymphoma
Yıl: 2021 Cilt: 5 Sayı: 2 Sayfa Aralığı: 283 - 288 Metin Dili: İngilizce DOI: 10.14744/ejmi.2021.62268 İndeks Tarihi: 24-01-2022
Genetic Abnormalities Detected in Non-Hodgkin Lymphoma
Öz: Objectives: To investigate the association between clinical features and fluorescence in situ hybridization (FISH) resultsof patients with non -Hodgkin lymphoma (NHL). The advances in molecular biology, cytogenetics and immunology facilitated the understanding of the pathogenesisof lymphoma. Although there are some basic prognostic indicators, the prognostic importance of genetic factors isgradually increasing. Methods: Fifty six patients who underwent genetic analysis before therapy, were evaluated retrospectively. Deparaf finized lymph node sections were used. Patients were divided into two groups according to the presence of geneticdisorder. The groups were compared in terms of clinical features, laboratory parameters and survival. Results: Genetic abnormality was present in 33 of 56 patients. The most common genetic abnormality was MYC/IGH2rearrangement. There was no difference between the survival of the groups. There was a positive correlation between Bsymptoms and the presence of genetic disorder and a negative correlation between leukocyte count and the presenceof genetic abnormality. Conclusion: Despite including small number of patients and heterogeneous histological NHL subtypes, our study mayprovide contribution to the frequency and type of genetic abnormalities in patients with NHL in Turkey.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik
- 1. Offit K, Wong G, Filippa DA, Tao Y, Chaganti RS. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood 1991;7:1508–15.
- 2. Johansson B, Mertens F, Mitelman F. Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood 1995;86:3905– 14.
- 3. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497–506.
- 4. Couronné L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 2012;366:95–6.
- 5. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011;118:6904–8.
- 6. Kaneko Y, Rowley JD, Variakojis D, Haren JM, Ueshima Y, Daly K, et al. Prognostic implications of karyotype and morphology in patients with non-Hodgkin's lymphoma. Int J Cancer 1983;32:683–92.
- 7. Bloomfield CD, Arthur DC, Frizzera G, Levine EG, Peterson BA, Gajl-Peczalska KJ. Nonrandom chromosome abnormalities in lymphoma. Cancer Res 1983;43:2975–84.
- 8. Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, Bloomfield CD. There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas. Blood 1985;66:1414–22.
- 9. Koduru PR, Filippa DA, Richardson ME, Jhanwar SC, Chaganti SR, Koziner B, et al. Cytogenetic and histologic correlations in malignant lymphoma. Blood 1987;69:97–102.
- 10. Levine EG, Arthur DC, Gajl-Peczalska KJ, LeBien TW, Peterson BA, Hurd DD, et al. Correlations between immunological phenotype and karyotype in malignant lymphoma. Cancer Res. 1986;46:6481–8
- 11. Richardson ME, Chen QG, Filippa DA, Offit K, Hampton A, Koduru PR, et al. Intermediate- to high-grade histology of lymphomas carrying t(14;18) is associated with additional nonrandom chromosome changes. Blood 1987;70:444–7.
- 12. Armitage JO, Sanger WG, Weisenburger DD, Harrington DS, Linder J, Bierman PJ, et al. Correlation of secondary cytogenetic abnormalities with histologic appearance in non-Hodgkin's lymphomas bearing t(14;18)(q32;q21). J Natl Cancer Inst 1988;80:576–80.
- 13. Kristoffersson U, Heim S, Mandahl N, Olsson H, Ranstam J, Akerman M, et al. Prognostic implication of cytogenetic findings in 106 patients with non-Hodgkin lymphoma. Cancer Genet Cytogenet 1987;25:55–64.
- 14. Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, Bloomfield CD. Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma. Ann Intern Med 1988;108:14–20
- 15. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989;320:1047–54.
- 16. Offit K, Koduru PR, Hollis R, Filippa D, Jhanwar SC, Clarkson BC, et al. 18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. Br J Haematol 1989;72:178– 83. 17. Cabanillas F, Pathak S, Grant G, Hagemeister F, McLaughlin P, Swan F, et al. Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med 1989;87:167–72.
- 18. Schouten HC, Sanger WG, Weisenburger DD, Anderson J, Armitage JO. Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: associations with histology, clinical characteristics, and treatment outcome. The Nebraska Lymphoma Study Group. Blood 1990;75:1841–7
- 19. Xu L, Zou XG, Wang X, Hairesa AB, Liu JJ. Genetic characteristics of non-Hodgkin lymphoma in ethnic Uighur people, and their clinical significance. Genet Mol Res 2016 Dec 2;15. doi: 10.4238/gmr15048960. [Epub ahead of print]. 20. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med 1987;316:79–84.
- 21. Kahl B, Yang D. Marginal zone lymphomas: management of nodal, splenic, and MALT NHL. Hematology Am Soc Hematol Educ Program 2008:359–64
- 22. Zhang ZZ, Ni XZ, Shen YY. Study of t(14;18) chromosomal translocation and bcl-2 gene amplification in gastrointestinal diffuse large B-cell lymphoma. J Surg Conc Prac 2010;15:143– 7.
- 23. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer.2004;4:644–53.
- 24. Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, et al. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget 2016;7:2401–16.
- 25. Caponetti GC, Dave BJ, Perry AM, Smith LM, Jain S, Meyer PN, et al. Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome. Leuk Lymphoma 2015;56:3082–9.
- 26. Gong JY, Zhang YZ, Zhang JD, Zhang W, Li JQ, Ru K, et al. [Clinical characteristics of high-grade B-cell lymphomas with rearrangement of MYC, bcl-6 and bcl-2]. Zhonghua Bing Li Xue Za Zhi 2018;47:14–8.
- 27. Kawamoto K, Miyoshi H, Yoshida N, Nakamura N, Ohshima K, Sone H, et al. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma. Cancer Sci 2016;107:853–61.
- 28. Ikegami K, Nakamura S, Esaki M, Yanai S, Hirahashi M, Oda Y, et al. Prognostic value of chromosomal translocations in small-bowel diffuse large B-cell lymphoma. Histopathology 2016;68:199–209.
- 29. Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood 2017;129:473– 83.
- 30. Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, et al. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest 2016;126:3351–62
| APA | BULDUK T, GÜNDÜZ E, DURAK ARAS B, EMİR B, IŞIKSOY S (2021). Genetic Abnormalities Detected in Non-Hodgkin Lymphoma. , 283 - 288. 10.14744/ejmi.2021.62268 |
| Chicago | BULDUK TUBA,GÜNDÜZ Eren,DURAK ARAS Beyhan,EMİR Büşra,IŞIKSOY Serap Genetic Abnormalities Detected in Non-Hodgkin Lymphoma. (2021): 283 - 288. 10.14744/ejmi.2021.62268 |
| MLA | BULDUK TUBA,GÜNDÜZ Eren,DURAK ARAS Beyhan,EMİR Büşra,IŞIKSOY Serap Genetic Abnormalities Detected in Non-Hodgkin Lymphoma. , 2021, ss.283 - 288. 10.14744/ejmi.2021.62268 |
| AMA | BULDUK T,GÜNDÜZ E,DURAK ARAS B,EMİR B,IŞIKSOY S Genetic Abnormalities Detected in Non-Hodgkin Lymphoma. . 2021; 283 - 288. 10.14744/ejmi.2021.62268 |
| Vancouver | BULDUK T,GÜNDÜZ E,DURAK ARAS B,EMİR B,IŞIKSOY S Genetic Abnormalities Detected in Non-Hodgkin Lymphoma. . 2021; 283 - 288. 10.14744/ejmi.2021.62268 |
| IEEE | BULDUK T,GÜNDÜZ E,DURAK ARAS B,EMİR B,IŞIKSOY S "Genetic Abnormalities Detected in Non-Hodgkin Lymphoma." , ss.283 - 288, 2021. 10.14744/ejmi.2021.62268 |
| ISNAD | BULDUK, TUBA vd. "Genetic Abnormalities Detected in Non-Hodgkin Lymphoma". (2021), 283-288. https://doi.org/10.14744/ejmi.2021.62268 |
| APA | BULDUK T, GÜNDÜZ E, DURAK ARAS B, EMİR B, IŞIKSOY S (2021). Genetic Abnormalities Detected in Non-Hodgkin Lymphoma. Eurasian Journal of Medical Investigation, 5(2), 283 - 288. 10.14744/ejmi.2021.62268 |
| Chicago | BULDUK TUBA,GÜNDÜZ Eren,DURAK ARAS Beyhan,EMİR Büşra,IŞIKSOY Serap Genetic Abnormalities Detected in Non-Hodgkin Lymphoma. Eurasian Journal of Medical Investigation 5, no.2 (2021): 283 - 288. 10.14744/ejmi.2021.62268 |
| MLA | BULDUK TUBA,GÜNDÜZ Eren,DURAK ARAS Beyhan,EMİR Büşra,IŞIKSOY Serap Genetic Abnormalities Detected in Non-Hodgkin Lymphoma. Eurasian Journal of Medical Investigation, vol.5, no.2, 2021, ss.283 - 288. 10.14744/ejmi.2021.62268 |
| AMA | BULDUK T,GÜNDÜZ E,DURAK ARAS B,EMİR B,IŞIKSOY S Genetic Abnormalities Detected in Non-Hodgkin Lymphoma. Eurasian Journal of Medical Investigation. 2021; 5(2): 283 - 288. 10.14744/ejmi.2021.62268 |
| Vancouver | BULDUK T,GÜNDÜZ E,DURAK ARAS B,EMİR B,IŞIKSOY S Genetic Abnormalities Detected in Non-Hodgkin Lymphoma. Eurasian Journal of Medical Investigation. 2021; 5(2): 283 - 288. 10.14744/ejmi.2021.62268 |
| IEEE | BULDUK T,GÜNDÜZ E,DURAK ARAS B,EMİR B,IŞIKSOY S "Genetic Abnormalities Detected in Non-Hodgkin Lymphoma." Eurasian Journal of Medical Investigation, 5, ss.283 - 288, 2021. 10.14744/ejmi.2021.62268 |
| ISNAD | BULDUK, TUBA vd. "Genetic Abnormalities Detected in Non-Hodgkin Lymphoma". Eurasian Journal of Medical Investigation 5/2 (2021), 283-288. https://doi.org/10.14744/ejmi.2021.62268 |
